Literature DB >> 16517709

Induction of alloreactive CD4 T cell tolerance in molecular chimeras: a possible role for regulatory T cells.

Daron Forman1, Eun-Suk Kang, Chaorui Tian, Jesus Paez-Cortez, John Iacomini.   

Abstract

Induction of molecular chimerism following reconstitution of mice with autologous bone marrow cells expressing a retrovirally encoded allogeneic MHC class I Ag results in donor-specific tolerance. To investigate the mechanism by which CD4 T cells that recognize allogeneic MHC class I through the indirect pathway of Ag presentation are rendered tolerant in molecular chimeras, transgenic mice expressing a TCR on CD4 T cells specific for peptides derived from K(b) were used. CD4 T cells expressing the transgenic TCR were detected in mice reconstituted with bone marrow cells transduced with retroviruses carrying the gene encoding H-2K(b), albeit detection was at lower levels than in mice receiving mock-transduced bone marrow. Despite the presence of CD4 T cells expressing an alloreactive TCR, mice receiving H-2K(b)-transduced bone marrow permanently accepted K(b) disparate skin grafts. CD4+CD25+ T cells from mice reconstituted with H-2K(b)-transduced bone marrow prevented rejection of K(b) disparate skin grafts when adoptively transferred into immunodeficient mice along with effector T cells, suggesting that induction of molecular chimerism leads to the generation of donor specific regulatory T cells, which may be involved in preventing alloreactive CD4 T cell responses that lead to rejection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517709     DOI: 10.4049/jimmunol.176.6.3410

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Induction of transplantation tolerance to fully mismatched cardiac allografts by T cell mediated delivery of alloantigen.

Authors:  Chaorui Tian; Xueli Yuan; Peter T Jindra; Jessamyn Bagley; Mohamed H Sayegh; John Iacomini
Journal:  Clin Immunol       Date:  2010-05-08       Impact factor: 3.969

2.  Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease.

Authors:  Qiushi Liang; Eva C Vlaar; Fabio Catalano; Joon M Pijnenburg; Merel Stok; Yvette van Helsdingen; Arnold G Vulto; Wendy W J Unger; Ans T van der Ploeg; W W M Pim Pijnappel; Niek P van Til
Journal:  Mol Ther Methods Clin Dev       Date:  2022-05-04       Impact factor: 5.849

3.  Induction of transplantation tolerance by combining non-myeloablative conditioning with delivery of alloantigen by T cells.

Authors:  Chaorui Tian; Xueli Yuan; Jessamyn Bagley; Bruce R Blazar; Mohamed H Sayegh; John Iacomini
Journal:  Clin Immunol       Date:  2008-02-15       Impact factor: 3.969

4.  Tolerance induction in experimental autoimmune encephalomyelitis using non-myeloablative hematopoietic gene therapy with autoantigen.

Authors:  Herena Eixarch; Carmen Espejo; Alba Gómez; María José Mansilla; Mireia Castillo; Alexander Mildner; Francisco Vidal; Ramón Gimeno; Marco Prinz; Xavier Montalban; Jordi Barquinero
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

5.  Persistent molecular microchimerism induces long-term tolerance towards a clinically relevant respiratory allergen.

Authors:  U Baranyi; N Pilat; M Gattringer; B Linhart; C Klaus; E Schwaiger; J Iacomini; R Valenta; T Wekerle
Journal:  Clin Exp Allergy       Date:  2012-08       Impact factor: 5.018

6.  Tolerance to MHC class II disparate allografts through genetic modification of bone marrow.

Authors:  P T Jindra; S Tripathi; C Tian; J Iacomini; J Bagley
Journal:  Gene Ther       Date:  2012-07-26       Impact factor: 5.250

7.  Induction of Hematopoietic Microchimerism by Gene-Modified BMT Elicits Antigen-Specific B and T Cell Unresponsiveness toward Gene Therapy Products.

Authors:  Jérémie Martinet; Gwladys Bourdenet; Amine Meliani; Laetitia Jean; Sahil Adriouch; Jose L Cohen; Federico Mingozzi; Olivier Boyer
Journal:  Front Immunol       Date:  2016-09-15       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.